Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
about
Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose InterferonDNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes.Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma.Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.Ipilimumab in melanoma.Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma.Immunoplasticity in cutaneous melanoma: beyond pure morphology.The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.Prognostic significance of hematological profiles in melanoma patients.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN® (dendritic cell-based vaccine): a case report.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial.Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma.CANCER. How neutrophils promote metastasis.IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapyBaseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort StudyPrognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancerPretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
P2860
Q33904496-D59589E7-696A-4844-BB1A-C1132BF1B946Q36222815-FF066831-BEF8-497A-9189-874A220F7EB7Q36241273-7FD5547D-95CA-4017-A7AF-4BAACA65EEE4Q37606693-938AB35D-66C7-4530-8797-C413D1F57E7AQ37687133-918A05CC-0D3F-41BE-9DEB-E1F7968DCF41Q37718449-F89D6C91-DA41-42AE-B09C-70D9E7C31CA9Q38645338-9499E771-622F-4E85-866C-883F4166F96FQ38753031-C358C346-8F2C-487B-9A9F-4C6F285D4655Q38769899-CDF81B86-E36E-4A97-9FF6-7B7FCF2E6BC0Q38874383-CDBED7C0-F867-4C79-896C-257228AF33DCQ38893697-28267765-20A3-4CBB-90AF-CC82A625E3B8Q38902180-C1B7F076-9059-46CB-86EB-3CC927792F8BQ39067933-16E5128C-261B-4A99-B45E-E60191DB0FE8Q39341329-3C20C323-CECE-4C47-BBDF-2B055BDCDAAFQ39429983-06C42C70-3E3A-4F24-BF1A-6212CCD8138CQ40070782-F62B725F-5FEB-4CF1-B1D2-A65EE21FAED7Q40268169-CD0245C9-993F-4E29-8AC1-7F0AD205CE5FQ40723817-08FAB662-A9A1-4596-992D-6C1689F71904Q40964128-BE4643C8-8394-4813-840E-2B41C65767B6Q41899044-7BB1EBA6-3F49-47D5-BB97-4892D9790FC8Q42279459-AAFF1D82-5FCF-4549-BA17-56224469F0BBQ42369277-B24D8D0F-7376-4054-99A4-418295406A84Q46449589-D26BDEC9-AC98-4B81-82FD-56BEFBF921DDQ47331134-CD34E19B-FE13-4CA7-9FFB-678E98DCE1D0Q48115656-60F18552-75C2-4CDD-B419-09B89D6B1674Q48227716-3F648370-CDA6-4F32-B156-3F5A17A9AF1CQ48278429-C9BEC127-D754-44F5-8156-82E09CCB6127Q49766057-A57D277C-1FEC-425E-9318-998B1257B13BQ50016409-4577C0D2-6C3B-43E0-9D3C-55E28574CC1BQ50070316-B1A98554-7F43-4BD4-BA3B-1F3AE75CBF1BQ52671072-A54251ED-69EE-44F5-9357-B822243ACD2DQ52872621-31DAF437-7A3C-4B63-90FE-8CD9E0D36205Q53881415-0414A5F8-A25D-4253-B29B-E3EEEB63C8A4Q57067866-A1133ACE-9319-4B5E-9112-447F38786E55Q57070172-21EDC57C-D661-4121-A90B-2E3F8F720352Q58417608-5F8E06CA-D3DF-4398-A529-7DD61E431BD2Q58694427-CDC996F8-253F-4A39-A0FD-BC9D2C3DA38DQ58700048-2B3D8806-2BFE-43E1-B372-92D31E6C2A4B
P2860
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Baseline neutrophil-to-lymphoc ...... metastatic melanoma patients.
@ast
Baseline neutrophil-to-lymphoc ...... metastatic melanoma patients.
@en
type
label
Baseline neutrophil-to-lymphoc ...... metastatic melanoma patients.
@ast
Baseline neutrophil-to-lymphoc ...... metastatic melanoma patients.
@en
prefLabel
Baseline neutrophil-to-lymphoc ...... metastatic melanoma patients.
@ast
Baseline neutrophil-to-lymphoc ...... metastatic melanoma patients.
@en
P2093
P2860
P50
P356
P1476
Baseline neutrophil-to-lymphoc ...... metastatic melanoma patients.
@en
P2093
A Battaglia
A M Di Giacomo
E Cocorocchio
F De Galitiis
G C Antonini Cappellini
P2860
P2888
P304
P356
10.1038/BJC.2015.180
P407
P50
P577
2015-05-26T00:00:00Z
P6179
1013795487